NEW YORK, May 30 – Incyte Genomics and Iconix Pharmaceuticals announced on Wednesday a collaboration to develop and commercialize the next-generation of Iconix’s ChemExpress chemogenomic platform.

Incyte will exclusively market and sell ChemExpress, according to the companies. Iconix will integrate Incyte’s LifeExpress Lead databases into ChemExpress under an exclusive license from Incyte, the companies announced. Under the terms of the agreement, Incyte will make an equity investment in Iconix.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.